Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy

Journal of Supportive Oncology

Volumn 4, Issue 3, 2006, Pages 129-135

  Shasha, Daniel ^a   Williams, Denise ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE CALCULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PILOT STUDY; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS;

EID: 33645794746     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Williston Park) 2002;16(suppl):17-24.
2. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002;16:87-96.
3. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634. Published erratum in: J Natl Cancer Inst 2000;92:497.
4. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 1999;4:1-10.
5. Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366-373.
6. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-2221.
7. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
8. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
9. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
10. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
11. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
12. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-4134.
13. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
14. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa in patients not on chemotherapy - Canadian data. Semin Oncol 2002;29(suppl 8):75-80.
15. Gough IR, Furnival CM, Schilder L, Grove W. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983;19:1161-1165.
16. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales:a critical review. Psychol Med 1988;18:1007-1019.
17. Crawford J, Demetri GD, Gabrilove JL, et al. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer 2002;3:180-190.
18. Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-276.
19. Ross SD, Fahrbach K, Frame D, et al. The effect of anemia treatment on selected health-related quality-of-life domains:a systematic review. Clin Ther 2003;25:1786-1805.
20. Weiss MJ. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist 2003;8(suppl 3):18-29.
21. Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004;30:563-575.
22. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995;76:2319-2329.
23. Henry D, Abels RI. Recombinant human erythropoietin in the treatment of cancer chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994;21(suppl 3):21-28.
24. Smith RE Jr, Tchekmedyian NS, Chan D, et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003;88:1851-1858.
25. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.
26. Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer 2003;98:1578-1586.
27. Procrit® (epoetin alfa) full prescribing information. Raritan, NJ: Ortho Biotech Products, LP; 2005.
28. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004;9(suppl 5):18-30.
29. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647-657.
30. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-918.
31. Westphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002;88:150-159.
32. Rosti V, Pedrazzoli P, Ponchio L, et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 1993;78:208-212.
33. Selzer E, Wacheck V, Kodym R, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000;10:421-426.